Shi Guangbin, Ma Ke, Pappas George D, Qu Tingyu
The Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois at Chicago, 1601 West Taylor Street, Chicago, IL 60612, USA.
Neurol Res. 2008 Apr;30(3):217-22. doi: 10.1179/016164107X241674. Epub 2008 Feb 4.
Transplantation of adrenal chromaffin cells (CCs) that release endogenous opioid peptides and catecholamines produces significant antinociceptive effects in patients with terminal cancer pain. In clinical practice, however, obtaining a sufficient number of chromaffin cells may not be possible because of the limited availability of human adrenal tissue. Recent works have shown that fusion of bone marrow-derived cells with differentiated cells can occur spontaneously in vivo and acquire the phenotype of the recipient cells. In this study, we investigated the possibility of producing chromaffin-like cells by fusing human bone marrow-derived mesenchymal stem cells (MeSCs) with post-mitotic porcine CCs in vitro with the application of polyethylene glycol (PEG).
Before cell-to-cell fusion was initiated, MeSCs and CCs were labeled by fluorescence dyes DiO (green) and Dil (red), respectively. The hybrid cells generated by PEG-mediated fusion expressed a DiO and Dil double-staining with estimated fusion efficiency at approximately 40% of the total cell population. Further immunocytochemical examination for tyrosine hydroxylase and methionine enkephalin (markers for CCs) demonstrated positive immuno-reactivity in these hybrid cells 2 weeks post-fusion. More interestingly, some of the hybrid cells showed bromodeoxyuridine (BrdU)-positive immunostaining in the nuclei.
Our results show that these hybrid cells fused by CCs and MeSCs express some characteristics of the CC phenotype. A subpopulation of these hybrid cells are dividing cells with positive BrdU immunostaining, suggesting that a novel cellular production could be developed by a "reprogramming" mechanism through the application of targeted cell fusion strategies.
移植能释放内源性阿片肽和儿茶酚胺的肾上腺嗜铬细胞(CCs)可对晚期癌痛患者产生显著的镇痛作用。然而在临床实践中,由于人类肾上腺组织来源有限,可能无法获得足够数量的嗜铬细胞。近期研究表明,骨髓来源的细胞与分化细胞在体内可自发融合,并获得受体细胞的表型。在本研究中,我们探讨了通过聚乙二醇(PEG)介导,使人骨髓来源的间充质干细胞(MeSCs)与有丝分裂后的猪CCs在体外融合,从而产生嗜铬样细胞的可能性。
在细胞间融合开始前,分别用荧光染料DiO(绿色)和Dil(红色)标记MeSCs和CCs。PEG介导融合产生的杂交细胞呈现DiO和Dil双重染色,估计融合效率约为总细胞群体的40%。融合后2周,对这些杂交细胞进行酪氨酸羟化酶和甲硫氨酸脑啡肽(CCs的标志物)的进一步免疫细胞化学检测,结果显示免疫反应呈阳性。更有趣的是,部分杂交细胞核内呈现溴脱氧尿苷(BrdU)阳性免疫染色。
我们的结果表明,这些由CCs和MeSCs融合产生的杂交细胞表达了CC表型的一些特征。这些杂交细胞中的一个亚群是BrdU免疫染色呈阳性的分裂细胞,这表明通过应用靶向细胞融合策略,可能通过“重编程”机制开发一种新的细胞生成方法。